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TENOFOVIR GEL  – THE NEW HIV PREVENTION 
‘BANKER’?
Most of South Africa and the world’s 
top HIV/AIDS scientists are ‘excited 
and hopeful’ about the first-ever trial of 
a vaginal microbicide gel containing the 
highly effective ARV agent tenofovir, 
launched in Durban last month.
The test product, even if partially 
successful, has profound self-protection 
implications for millions of HIV-
vulnerable sub-Saharan women, with 
the potential to directly impact the 
dynamics of HIV transmission.
With highly enhanced adherence 
potential (it needs application within 
12 hours before and after coitus) and 
a sophisticated ‘chain terminator’ cell 
mechanism,  tenofovir gel has already 
proved an effective barrier to HIV 
infection in monkeys.
Until now microbicide gels had to 
be applied within, at most, an hour of 
coitus.
Tenofovir is one of the most effective 
new-generation antiretrovirals (until 
now in oral form) because of its minimal 
side-effects, high genetic barrier for 
resistance and long half-life.
Different  to controversial 
predecessors
Unlike the controversial two failed 
microbicides (Ushercell cellulose 
sulphate-based vaginal gel and 
nonoxynol-9), where trial participants 
sero-converted, the tenofovir gel does 
not act in the vaginal lumen to kill 
the virus. Instead, the drug is rapidly 
absorbed into the tissue and blood 
cells where it prevents the virus from 
growing.
With a formulation of just 1% 
tenofovir in the gel, the researchers are 
aiming at further reducing the chances 
of resistance developing. One of the 
most exciting ‘bonus’ prospects is that 
even if a participant becomes infected, 
the drug may have a major impact in 
slowing the progression of the disease.
Says Henry Gabelnick,  director 
of CONRAD, the international 
reproductive health foundation backing 
the project, ‘we’ve been trying to get a 
microbicide going since 1998 and we’re 
very enthusiastic about tenofovir’.
Adds Doug Taylor, Associate 
Director of BioStatistics for Family 
Health International, the other major 
international co-sponsor, ‘this product 
has a very good chance of success and 
the investigators are best suited to make 
that happen’. 
While the final data on what went 
wrong with the Ushercell trial remained 
outstanding at the time of writing, 
researchers believe nonoxynol-9 harmed 
participants by causing lesions in the 
vagina.
Results on the recently completed 
Carraguard microbicide study (done 
at Medunsa, Durban and Cape Town) 
are expected in the next 4 months 
(Carraguard prevents the virus from 
attaching to cells in the vagina).
Momentum ‘vital’ argues Karim
Lead investigator and Director of the 
Centre for the AIDS Programme of 
Research in South Africa (Caprisa), 
Professor Salim Abdool Karim, said 
3 microbicide trials had so far been 
stopped for futility and 2 for harm.
‘In reality we’ve had a series 
of disappointments, but to retain 
perspective you must remember that 
there’ve been even fewer trials for an 
HIV vaccine – and you don’t see them 
giving up! We have to keep a clear focus 
on our goal to find a woman-controlled 
HIV prevention method – I think that’s 
the challenge,’ he added.
The tenofovir trial is being conducted 
among 1 000 HIV-negative women 
attending the Ethekwini Clinical 
Research Site in Durban and the rural 
Mafakathini clinic at Vulindlela, 90 km 
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away.  The cohort includes outpatients 
at the Ethekwini Clinic and Durban sex 
workers, among whom general HIV 
prevalence stands at 55%.
Karim said this identical figure in 
both groups ‘just illustrates the diffuse 
nature of the pandemic’.
Should the results of this (phase 2b) 
study suggest a partially protective 
effect against HIV, then a full-scale 
phase 3 trial may be needed to produce 
definitive results.
After 4 years of preparing their 
research teams, Karim and his wife 
Quarraisha (Associate Scientific 
Director, Caprisa) took selected health 
journalists on a comprehensive tour of 
the facilities and outlined the trial on 29 
May this year.
‘This is the litmus test. This is 
where the rubber hits the road,’ said 
Quarraisha Abdool Karim. The Durban 
duo is considered to be among the 
world’s top AIDS researchers and have 
over 2 decades of experience in the field.
Home-grown research and 
development
The tenofovir trial is the first ever 
microbicide partnership led by a 
developing country institution. It is also 
the first to secure upfront public sector 
pricing for South African Development 
Community countries plus a voluntary 
licence for local manufacture (if 
cheaper).
Significantly, the study is backed by 
Lifelab, a biotechnology innovation 
vehicle set up by the Department of 
Science and Technology. Lifelab’s CEO, 
Blessed Okole, said his company was 
already conducting negotiations with 
local manufacturers to provide generic 
tenofovir, should the trials succeed.
Quarraisha Abdool Karim said it was 
‘a travesty’ that only 6 microbicides 
had so far gone to trial when 70% of the 
world’s HIV-infected women lived in 
sub-Saharan Africa.
Most major drug companies were 
self-evidently more interested in 
the far greater payoff of developing 
a curative rather than a preventive 
product. Gilead, the manufacturers and 
suppliers of tenofovir, have pledged 
full co-operation with Caprisa to ensure 
affordable access, especially where 
needs were greatest, should the trial hit 
the jackpot.
Caprisa’s leader of ‘targeted AIDS 
interventions’ for the rural area of 
the study (Mafakathini near Bulwer), 
Ms Gethwana Makhaye, said HIV 
prevalence among local women there 
aged under 20 had leapt from 15% to 
27% between 2001 and 2004.
For women between 20 and 29, this 
had rose from 39% to 66% over the same 
period.
The first government clinic onto 
which the comprehensive Caprisa 
health care facility has been added, was 
only built in 1998.
Extensive consultation with the 
amakhosi, indunas, women’s groups, 
community leaders plus imbizos at 
churches, schools and NGO sites had 
led to the formation of community 
research groups that now met regularly 
to discuss the impending study.
Makhaye quoted one local chief who, 
when first asked how he felt about the 
research, replied tellingly, ‘what kind of 
a leader would I be if I had nobody left 
to lead?’
‘i-Five-rands’
Salim Abdool Karim revealed, to 
general laughter, that when news of a 
sister AIDS treatment project first began 
spreading in the area, it soon became 
known as the ‘i-Five-rands’  after the 
mispronounciation of efavirenz, an 
antiretroviral drug widely referred to in 
community AIDS treatment education 
programmes.  The trial is being 
integrated into the same facilities which 
provide a comprehensive Caprisa HIV/
AIDS VCT, prevention, ART and care 
programme.
Quarraisha Abdool Karim explained 
that, by necessity, they had to embrace 
large cohorts to identify women who 
had not used condoms or face turning 
it into an exercise in futility. The study 
would however take into account any 
additional benefit of the gel when 
used by participants in coital acts that 
involved condoms.
She said the gel had no contraceptive 
function and did not act against other 
STDs.
‘We need to prove that we have a 
product that can prevent HIV infection – 
further down the line there will be more 
stratification to determine if it has any 
benefit on STDs and pregnancy,’ she 
added.
Asked what happened if a participant 
fell pregnant, she said they would be 
advised to stop using the gel, referred to 
an antenatal clinic and then, depending 
on the outcome of the pregnancy, 
allowed to rejoin the trial.
The wellbeing of all participants 
was ‘paramount’, with condoms 
and frequent prevention counselling 
provided to all participants. Those who 
had unprotected sex with an infected 
partner during the study, or anyone 
who sero-converted during the follow-
up period, had several choices. These 
included taking part in one of Caprisa’s 
long-term acute infection cohort studies 
that had excellent care, ARV and 
support systems or being referred to 
their preferred AIDS care provider.
‘People must always come first,’ she 
emphasised, adding that the study had 
rigorous scientific and ethical oversight 
and approval.
Cate Hankins, chief scientific 
advisor to UNAIDS, told Izindaba 
that, if successful, an ARV microbicide 
gel would dramatically increase the 
prevention/treatment options available 
to clinicians. Any efficacy would be 
highly significant, ‘especially in a 
situation where most women cannot 
negotiate the use of a condom and 
female condoms are too expensive’.
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